TirzepatideResearch
The SURMOUNT clinical program demonstrated up to 22.5% body weight reduction with tirzepatide — the first dual incretin receptor agonist targeting both GIP and GLP-1 pathways simultaneously.
22.5%
Max weight loss
SURMOUNT-1 at 72 weeks
Dual
Receptor agonist
GIP + GLP-1 simultaneous
GIP+GLP-1
Incretin targets
First-in-class mechanism
GLP-2 T Profile
- Mechanism
- Dual GIP/GLP-1 Agonist
- Trial
- SURMOUNT-1/2/3/4
- Max Dose
- 15mg weekly
- Weight Reduction
- Up to 22.5%
- HbA1c Reduction
- Up to 2.3%
- CAS
- 2023788-19-2
Research use only — not for human consumption
The Dual Agonist Advantage
- GIP + GLP-1 simultaneous receptor activation — first-in-class incretin synergy
- 22.5% weight loss vs. 14.9% semaglutide — superior efficacy across all SURMOUNT arms
- Superior HbA1c reduction: −2.3% vs. −1.9% with GLP-1-only agonists
Research Areas
GLP-1/GIP dual receptor agonism and its metabolic implications
Dual Agonist Biology
GLP-1R + GIPR co-activation — the mechanistic basis of incretin synergy and superior metabolic efficacy.
ExploreWeight Loss Research
SURMOUNT-1 through 4 data — up to 22.5% body weight reduction at 72 weeks across phase 3 trials.
ExploreCardiovascular Protection
SURPASS-CVOT outcomes — 15% MACE reduction vs. active GLP-1 comparator in high-risk subjects.
ExploreGlucose & Insulin
51% T2D normoglycemia rate, HbA1c −2.3% reduction — superior glycemic control vs. GLP-1-only agonists.
ExploreFeatured Products
Research-grade GLP-2 T peptides
GLP-2 T 15mg
Tirzepatide dual GIP/GLP-1 receptor agonist, 39 amino acids with C20 lipidation. Supplied as lyophilized powder for laboratory research applications.
CAS: 2023788-19-2
Research Categories
Explore tirzepatide by research application
Dual GIP/GLP-1 Research
Research on tirzepatide's dual GIP and GLP-1 receptor agonism mechanisms.
Metabolic & Weight Research
SURMOUNT trial data and metabolic research on tirzepatide's weight reduction mechanisms.
Glucose & Insulin Research
Tirzepatide research on glucose homeostasis, insulin secretion, and beta-cell function.
Cardiovascular Research
Tirzepatide cardiovascular and metabolic syndrome research.
Multi-Pack Research Bundles
Tirzepatide multi-pack bundles for extended research protocols.
The Most Studied Dual Agonist
2,539
Trial Participants
SURMOUNT-1 cohort
22.5%
Max Weight Loss
At 72 weeks, 15mg dose
+0.4%
Placebo Comparator
vs. tirzepatide −22.5%
The SURMOUNT clinical program — four phase 3 trials enrolling over 2,500 participants each — established tirzepatide as the most efficacious weight-loss compound studied to date. SURMOUNT-1 demonstrated 22.5% mean body weight reduction at 72 weeks with the 15mg dose, surpassing all prior GLP-1 monotherapy benchmarks. As the first dual GIP/GLP-1 receptor agonist, tirzepatide provides a unique model for studying incretin synergy, adipose tissue remodeling, and the metabolic consequences of simultaneous GIP and GLP-1 receptor activation.
Purity Certified
All peptides independently tested to >98% purity via HPLC. Certificates of analysis available on request.
Free Shipping
Complimentary shipping on all orders over $200. Fast, discreet delivery to your research facility.
Research Grade
Lyophilized tirzepatide peptides produced to research-grade standards. For laboratory use only.
Begin Your Peptide Scientists
Research-grade tirzepatide available in 15mg, 30mg, and 60mg vials with third-party HPLC purity certification and certificates of analysis. Free shipping on orders over $200.